DUBLIN, April 29,
2024 /PRNewswire/ -- Theravance Biopharma, Inc.
(NASDAQ: TBPH) will report its first quarter 2024 financial results
and provide a business update after market close on Monday, May 13, 2024. An accompanying conference
call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm
PT/10:00 pm IST) that day.
Conference Call Information
To participate in the live call by telephone, please
pre-register here. Those interested in listening to the conference
call live via the internet may do so by visiting Theravance
Biopharma's website at www.theravance.com, under the Investors
section, Events and Presentations.
A replay of the webcast will be available on Theravance
Biopharma's website for 30 days through June
12, 2024.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines
that Make a Difference® in people's lives. In
pursuit of its purpose, Theravance Biopharma leverages decades of
expertise, which has led to the development of FDA-approved
YUPELRI® (revefenacin) inhalation solution indicated for
the maintenance treatment of patients with chronic obstructive
pulmonary disease (COPD). Ampreloxetine, its late-stage
investigational once-daily norepinephrine reuptake inhibitor in
development for symptomatic neurogenic orthostatic hypotension
(nOH) in patients with Multiple System Atrophy (MSA), has the
potential to be a first in class therapy effective in treating a
constellation of cardinal symptoms in MSA patients. The Company is
committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the
Cross/Star logo are registered trademarks of the Theravance
Biopharma group of companies (in the U.S. and
certain other countries).
YUPELRI® is a registered trademark of Mylan
Specialty L.P., a Viatris company. Trademarks, trade names or
service marks of other companies appearing in this press release
are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download
multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-first-quarter-2024-financial-results-on-may-13-2024-302129720.html
SOURCE Theravance Biopharma, Inc.